The Life Sciences team advised Apnimed, Inc. in its joint venture with Shionogi & Co., Ltd. to develop novel pharmacologic therapies to treat obstructive sleep apnea (OSA) and other sleep disorders.
The newly formed joint venture, Shionogi-Apnimed Sleep Science, LLC, initially focuses on accelerating the discovery, preclinical and clinical development of novel pharmacologic solutions designed to address the complex pathology of OSA. Shionogi also made an equity investment in Apnimed.
Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea – patients with obstructive sleep apnea could benefit from treatment with a safe and effective oral medication dosed once daily at bedtime. Apnimed continues to progress its lead programs, AD109 (now in Phase 3 trials) and AD504 (in Phase 2 trials), independently of this joint venture.
Shionogi is a leading global research-driven pharmaceutical company based in Japan dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and well-being of the patients we serve.”
The Goodwin team was led by Tim Atkins, Dave Gallagher, Kahn Wiedis, Daniel Karelitz, Nicole Brock and Chris Zhao, with invaluable assistance from Troy Root.
For more details, read the press release and coverage in Endpoints News and Law360.